<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047788</url>
  </required_header>
  <id_info>
    <org_study_id>6474IL/0004</org_study_id>
    <secondary_id>IND.145(Canada)</secondary_id>
    <nct_id>NCT00047788</nct_id>
    <nct_alias>NCT00052741</nct_alias>
  </id_info>
  <brief_title>Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer</brief_title>
  <official_title>A Phase Two Study of ZD6474 in Patients With Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective is to assess the efficacy of ZD6474 when given orally to patients with
      relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be
      entered on study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEGF-receptor tyrosine kinase (KDR)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of multiple myeloma.

          -  Patients must have a minimum serum M-protein level &gt;=10g/L on serum protein
             electrophoresis or for patients with light chain only disease, a minimum Bence-Jones
             protein of 1g/24 hr.

          -  Patients must have received prior treatment for multiple myeloma: patients may have
             received 1 or 2 prior regimens of oral alkylating based chemotherapy and must have
             relapsed following treatment (&gt;= 3 months) OR patients may have relapsed following
             high dose chemotherapy and SCT as first line treatment provided they have not had any
             other treatment.

          -  Lab at inclusion of AGC &gt;= 1.0 x10_9/L and platelets &gt;= 50 x10_9/L Bilirubin, AST
             and/or ALT &lt;= 1.5 x UNL; creatinine &lt; 2 x UNL, Potassium &gt;= 4.0 mmol/L; calcium and
             magnesium within normal limitsÂ·

          -  Patients may not have had &gt; 2 prior regimens of chemotherapy and/or prior thalidomide
             treatment.

          -  Patients may not have had any non-alkylating based chemotherapy.

        Exclusion Criteria:

          -  Patients with a history of other malignancies, except: adequately treated non-melanoma
             skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for &gt;= 5 years.

          -  Pregnant or lactating women. Women of childbearing potential must have a negative
             pregnancy test within 7 days prior to registration and must be using effective
             contraception throughout the study.

          -  Patients who have relapsed during treatment with oral alkylating chemotherapy.

          -  Patients who have received more than 2 prior regimens of chemotherapy.

          -  Patients who have received excluded medication or have excluded medical conditions.

          -  Patients who have received any non-alkylating based chemotherapy regimens as initial
             therapy, or as therapy for recurrent disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2002</study_first_submitted>
  <study_first_submitted_qc>October 18, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2002</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

